Cyclacel Pharmaceuticals (NASDAQ:BGMS) Trading 10.7% Higher – Should You Buy?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS)’s stock price was up 10.7% during trading on Thursday . The company traded as high as $0.93 and last traded at $0.9216. Approximately 19,152 shares were traded during trading, an increase of 14% from the average daily volume of 16,782 shares. The stock had previously closed at $0.8326.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Cyclacel Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Cyclacel Pharmaceuticals Stock Performance

The firm has a market cap of $4.97 million, a price-to-earnings ratio of -0.25 and a beta of -0.40. The stock has a 50-day moving average of $0.91 and a 200-day moving average of $0.95.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.08) earnings per share for the quarter. The firm had revenue of $0.34 million for the quarter. Cyclacel Pharmaceuticals had a negative return on equity of 31.60% and a negative net margin of 118.27%.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.